|Forum - Stocks For A Different Jungle
||If it belongs at the Pit it doesn't belong here.|
|From: blacksheep (Rep: 307) reply to blacksheep||Date: 06/02/2017 09:49|
|Forum: Stocks For A Different Jungle - Msg #19109||Thread #673930646 (Rec: 0) |
|Re: Significant Insider buying=>In a couple OCT 50C @9.85 for a look.|
| Reply to blacksheep - Msg #19108 - 06/02/2017 07:14|
Significant Insider buying.
One biotechnology player that insiders are snapping up a huge amount of stock in is Bioverativ (BIVV) , which focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders.
Bioverativ has a market cap of $5.8 billion. This stock trades at a reasonable valuation, with a forward price-to-earnings of 16.8. Its estimated growth rate for this year 27.8%, and for next year it's pegged at 17%. This is a cash-rich company, since its total cash position is $358.70 million and its total debt is zero.
A director just bought 920,000 shares, or $51.30 million worth of stock, at $54.16 to $57.21 per share.
If you're bullish on Bioverativ, then I would look for long-biased trades as long as this stock is trending above key support at $51.06 and then once it breaks out above resistance at $57.83 to its all-time high of $59.50 with volume near or above its three-month average of 1.37 million shares. Some possible upside targets off that breakout are $65 to $70, or even $75 a share.
TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.